Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer?

Urology Annals

Volumn 7, Issue 1, 2015, Pages 26-30

  Sultan, Asfia ^a   Rizvi, Meher ^a   Khan, Fatima ^a   Sami, Hiba ^a   Shukla, Indu ^a   Khan, Haris M ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Enterobacteriaceae; fosfomycin; muti drug resistant; urinary tract infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE AMPC; CEFEPIME; CEFIXIME; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTRIAXONE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; METALLO BETA LACTAMASE; NORFLOXACIN; OFLOXACIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SPARFLOXACIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84921033739     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.148585     Document Type: Article

References (24)

1. Stamm WE, Norrby SR. Urinary tract infections: Disease panorama and challenges. J Infect Dis 2001;183 Suppl 1:S1-4.
2. Grude N, Tveten Y, Kristiansen BE. Urinary tract infections in Norway: Bacterial etiology and susceptibility. A retrospective study of clinical isolates. Clin Microbiol Infect 2001;7:543-7.
3. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: Use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77.
4. Rizvi M, Khan F, Shukla I, Malik A, Shaheen. Rising prevalence of antimicrobial resistance in urinary tract infections during pregnancy: Necessity for exploring newer treatment options. J Lab Physicians 2011;3:98-103.
5. Beckford-Ball J. Management of suspected bacterial urinary tract infection. Nurs Times 2006;102:25-6.
6. Girou E, Rioux C, Brun-Buisson C, Lobel B, Infection Committee of the French Association of Urology. The postoperative bacteriuria score: A new way to predict nosocomial infection after prostate surgery. Infect Control Hosp Epidemiol 2006;27:847-54.
7. Collee JG, Fraser AG, Marmion BP, Simmons A. Tests for the identification of bacteria. In: Collee JG, Miles RS, Watt B, editors. Mackey and McCartney Practical Medical Microbiology. 14 th ed. New Delhi: Elsevier; 2006. p. 131-49.
8. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001;7:88-91.
9. Rizvi M, Fatima N, Rashid M, Shukla I, Malik A, Usman A, et al. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay. J Infect Dev Ctries 2009;3:177-86.
10. Clinical and Laboratory Standards Institute 2003. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement: Approved Standards M100-S18. Baltimore, USA: Clinical and Laboratory Standards Institute; 2008.
11. Okonko IO, Ijandipe LA, Ilusanya AO, Donbraye-Emmanuel OB, Ejembi J, Udeze AO, et al. Incidence of UTI among pregnant women in Ibadan South-Western Nigeria. Afr J Biotechnol 2009;8:6649-57.
12. Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL and Amp-C beta-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res 2008;127:85-8.
13. Moyo SJ, Aboud S, Kasubi M, Maselle SY. Bacterial isolates and drug susceptibility patterns of urinary tract infection among pregnant women at Muhimbili National Hospital in Tanzania. Tanzan J Health Res 2010;12:236-40.
14. Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum â-lactamases and ampc production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Lab Physicians 2013;5:90-3.
15. Ruxer J, Mozdzan M, Siejka A, Loba J, Markuszewski L. Fosfomycin and nitrofurantoin in the treatment of recurrent urinary tract infections in type 2 diabetic women: A preliminary report. Diabetol Dow i Klin 2006;6:277-282.
16. Kobayashi S, Kuzuyama T, Seto H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. Antimicrob Agents Chemother 2000;44:647-50.
17. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis 2010;10:43-50.
18. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010;22:355-7.
19. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009;53:4508-10.
20. Rubin RH, Beam TR Jr, Stamm WE. An approach to evaluating antibacterial agents in the treatment of urinary tract infection. Clin Infect Dis 1992;14 Suppl 2:S246-51.
21. Shrestha NK, Chua JD, Tuohy MJ, Wilson DA, Procop GW, Longworth DL, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: Potential utility of fosfomycin. Scand J Infect Dis 2003;35:12-4.
22. Barry AL, Fuchs PC. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob Agents Chemother 1991;35:1235-8.
23. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother 2011;55:4295-301.
24. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010;65:2459-63.